1. Opening Hook
It’s not every day a pharma company hosts a “special update” call to announce—wait for it—another top-level exit. 🫠 Cohance Lifesciences (formerly Suven Pharma) started its Tuesday evening explaining why yet another MD packed his bags, while promising that “the vision remains unchanged.” Investors sighed in déjà vu, analysts nodded politely, and the new COO—still unnamed—became the most anticipated hire since OpenAI’s board saga. Vivek Sharma, ever the optimist, assured that the $1 billion dream by 2030 is “firmly on track.” If only leadership tenures lasted as long as that vision.
(Stick around—because midway through, the CEO justifies six mergers, one resignation, and a $1 billion fantasy all in a single breath.)
2. At a Glance
- MD Resigned: Dr. Prasada Raju steps down—calls it “personal priorities,” markets call it “pattern recognition.”
- New COO Coming Soon: A “techno-commercial” veteran, allegedly part-human, part PowerPoint.
- Three CEOs for Three Verticals: CDMO, API+, and Specialty Chemicals—each reporting directly to Vivek Sharma.
- $1 Billion by 2030 Goal: Because every pharma deck needs one big number.
- Attrition Watch: Stable “at the top,” says management, for now.
- U.S. FDA OI Classification: Minor issue (<1% EBITDA impact), major PR effort.
- Rebranding: New logo unveiled at CPhI Frankfurt—because branding solves everything.
3. Management’s Key Commentary
Vivek Sharma, Executive Chairman:
“Dr. Prasada Raju has resigned to continue his learning journey.”
(Translation: The only MBA left to complete was the exit interview.)
“We are reorganizing into three verticals—CDMO, API+, and Specialty Chemicals—with full accountability.”
(Translation: When in doubt, restructure.)
“A new COO joins soon to strengthen operations and execution.”
(Translation: Someone new to blame next quarter.) 😏
“We just completed four major customer orders successfully.”
(Translation: Phew,
